HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 10680.0
(-2.11%)
KRW 10680.0
(-2.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.7 Billion KRW | -17.8% |
| 2022 | -7.5 Billion KRW | 32.29% |
| 2021 | -11.08 Billion KRW | 1.6% |
| 2020 | -11.26 Billion KRW | 5.18% |
| 2019 | -11.88 Billion KRW | -276.58% |
| 2018 | -3.15 Billion KRW | 29.73% |
| 2017 | -4.49 Billion KRW | -11.19% |
| 2016 | -4.03 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.2 Billion KRW | -21.86% |
| 2024 Q1 | -2.63 Billion KRW | -2.15% |
| 2023 FY | -8.84 Billion KRW | -17.8% |
| 2023 Q2 | -2.62 Billion KRW | -76.54% |
| 2023 Q3 | -2.37 Billion KRW | 9.67% |
| 2023 Q4 | -2.57 Billion KRW | -8.64% |
| 2023 Q1 | -1.48 Billion KRW | 50.35% |
| 2022 Q2 | -789.46 Million KRW | -36.01% |
| 2022 FY | -7.5 Billion KRW | 32.29% |
| 2022 Q4 | -2.99 Billion KRW | 30.86% |
| 2022 Q3 | -4.33 Billion KRW | -448.66% |
| 2022 Q1 | -580.43 Million KRW | 80.0% |
| 2021 Q4 | -2.9 Billion KRW | -68.01% |
| 2021 Q3 | -1.72 Billion KRW | 0.0% |
| 2021 FY | -11.08 Billion KRW | 1.6% |
| 2020 FY | -11.26 Billion KRW | 5.18% |
| 2019 FY | -11.88 Billion KRW | -276.58% |
| 2018 FY | -3.15 Billion KRW | 29.73% |
| 2017 FY | -4.49 Billion KRW | -11.19% |
| 2016 FY | -4.03 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Co., Ltd. | -125.02 Billion KRW | 93.041% |
| iNtRON Biotechnology, Inc. | -3.28 Billion KRW | -164.851% |
| BINEX Co., Ltd. | 1.04 Billion KRW | 934.747% |
| Bioneer Corporation | 791.75 Million KRW | 1198.861% |
| Anterogen.Co.,Ltd. | -5.07 Billion KRW | -71.473% |
| MEDIPOST Co., Ltd. | -25.13 Billion KRW | 65.38% |
| CrystalGenomics, Inc. | -30.91 Billion KRW | 71.856% |
| Helixmith Co., Ltd | -35.24 Billion KRW | 75.315% |
| Chabiotech Co.,Ltd. | -9.42 Billion KRW | 7.691% |
| Medy-Tox Inc. | 17.32 Billion KRW | 150.226% |
| Peptron, Inc. | -15.6 Billion KRW | 44.24% |
| Amicogen, Inc. | 2.05 Billion KRW | 523.135% |
| Genexine, Inc. | -41.24 Billion KRW | 78.904% |
| LegoChem Biosciences, Inc. | -80.82 Billion KRW | 89.235% |
| ALTEOGEN Inc. | -9.73 Billion KRW | 10.646% |
| PharmaResearch Co., Ltd. | 100.81 Billion KRW | 108.63% |
| SillaJen, Inc. | -21.34 Billion KRW | 59.241% |
| JETEMA, Co., Ltd. | 2.63 Billion KRW | 430.351% |
| OliX Pharmaceuticals,Inc | -18.18 Billion KRW | 52.158% |
| Genomictree Inc. | -17.3 Billion KRW | 49.72% |
| MedPacto, Inc. | -28.75 Billion KRW | 69.74% |
| D&D Pharmatech | -13.48 Billion KRW | 35.488% |
| EASY BIO,Inc. | 20.63 Billion KRW | 142.17% |
| GI Innovation, Inc. | -55.6 Billion KRW | 84.353% |